Seek Returns logo

ALHC vs. ASND: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ALHC and ASND, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ASND stands out with 9.55 billion USD in market value—about 3.15× ALHC’s market cap of 3.03 billion USD.

ALHC’s beta of 1.33 points to much larger expected swings compared to ASND’s calmer 0.40, suggesting both higher upside and downside potential.

ASND is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALHC, which is purely domestic.

SymbolALHCASND
Company NameAlignment Healthcare, Inc.Ascendis Pharma A/S
CountryUSDK
SectorHealthcareHealthcare
IndustryMedical - Healthcare PlansBiotechnology
CEOMr. John E. KaoMr. Jan Moller Mikkelsen
Price15.33 USD158.1 USD
Market Cap3.03 billion USD9.55 billion USD
Beta1.330.40
ExchangeNASDAQNASDAQ
IPO DateMarch 26, 2021January 28, 2015
ADRNoYes

Performance Comparison

This chart compares the performance of ALHC and ASND over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ALHC and ASND based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • Neither ALHC nor ASND turned a profit—both carry negative P/E ratios of -32.75 and -24.55, underscoring continued losses that pressure their valuations.
  • Analysts assign negative forward PEG ratios to both ALHC (-1.11) and ASND (-2.23), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
  • ASND carries a sub-zero price-to-book ratio of -44.19, indicating negative equity. In contrast, ALHC (P/B 27.45) has positive book value.
  • ASND reports a negative Price-to-Free Cash Flow ratio of -27.43, showing a cash flow shortfall that could threaten its operational sustainability, while ALHC at 159.00 maintains positive cash flow.
SymbolALHCASND
Price-to-Earnings Ratio (P/E, TTM)-32.75-24.55
Forward PEG Ratio (TTM)-1.11-2.23
Price-to-Sales Ratio (P/S, TTM)1.0122.88
Price-to-Book Ratio (P/B, TTM)27.45-44.19
Price-to-Free Cash Flow Ratio (P/FCF, TTM)159.00-27.43
EV-to-EBITDA (TTM)-64.47-35.74
EV-to-Sales (TTM)0.8623.78
EV-to-Free Cash Flow (TTM)136.01-28.50

Dividend Comparison

Neither ALHC nor ASND currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolALHCASND
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ALHC and ASND, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND posts a quick ratio of 0.71, indicating limited coverage of short-term debts from its most liquid assets—while ALHC at 1.69 enjoys stronger liquidity resilience.
  • ASND has negative equity (debt-to-equity ratio -4.46), suggesting asset shortfalls, whereas ALHC at 0.07 preserves healthier equity coverage.
  • Both ALHC and ASND report negative interest coverage ratios (-2.98, -3.72), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
SymbolALHCASND
Current Ratio (TTM)1.691.04
Quick Ratio (TTM)1.690.71
Debt-to-Equity Ratio (TTM)0.07-4.46
Debt-to-Assets Ratio (TTM)0.010.80
Interest Coverage Ratio (TTM)-2.98-3.72